LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Leucocytes Identified by Automated Digital Morphology System

By LabMedica International staff writers
Posted on 31 Oct 2013
Image: CellaVision DM96 Digital Cell Morphology System (Photo courtesy of CellaVision).
Image: CellaVision DM96 Digital Cell Morphology System (Photo courtesy of CellaVision).
An automated digital cell morphology analyzer for determining leukocyte differential counts in peripheral blood smears (PBS) has been evaluated in a clinical laboratory.

The differential counting of peripheral blood leukocytes is one of the most frequently ordered laboratory tests by clinicians as it is an important test for the diagnosis of various hematologic diseases and systemic diseases. Improvements in laboratory technologies have benefited from the development of automated blood cell counters that have begun to replace the manual microscopic counting that is still performed in most laboratories.

Laboratory scientists at the University of Ulsan College of Medicine and Asan Medical Center (Seoul, Republic of Korea) examined a total of 308 peripheral blood samples with quantitative or qualitative abnormalities, for which complete blood counts had been ordered by clinicians. These samples were initially analyzed using the automatic blood cell analyzer Sysmex XE-2100 (Sysmex; Kobe, Japan), and the total leukocyte and differential counts were determined. Manual microscopic differential counts of 100 cells on each slide were separately performed by two independent well-trained laboratory technologists.

The slides were labeled and loaded into the CellaVision DM96 system (CellaVision AB; Lund, Sweden) after manual microscopic differential counting. In cases with a buffy coat preparation, the slides were prepared using samples prior to buffy coat preparation and labeled in the CellaVision DM96 system To evaluate the clinical relevance of the extension of cell counts up to 300 or 500 cells, which is the provided function by the CellaVision DM96 system, in the samples with low leukocyte count of less than 1,000 cells/μL, correlation analysis between the CellaVision DM96 system and manual count was performed.

The correlation coefficients between two methods were consistently high, ranged from 0.864 to 0.992. The sensitivity, specificity, positive predictive value, negative predictive values of this system for the identification of abnormalities was consistently high, especially for blast cells. When the instrument was instructed to count 300 or 500 cells from the operator, better performance was demonstrated than 100 cells in the leukopenic samples by sacrificing only 40 seconds/slide on average.

The authors concluded that the CellaVision DM96 system is useful in the clinical laboratory providing comparative accuracy compared with manual counts in samples with abnormalities. In leukopenic samples, report quality can be improved by ordering to count 300 or 500 cells from the operator without severe prolongation of turnaround time. The study was published on the October 2013 issue of the International Journal of Laboratory Hematology .

Related Links:

University of Ulsan College of Medicine and Asan Medical Center
Sysmex 
CellaVision AB 


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Automated MALDI-TOF MS System
EXS 3000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more